FINANCE/FUNDING ARTICLES

  • The Case For A Healthcare Futures Market
    The Case For A Healthcare Futures Market

    Now is the time to develop a novel financial instrument which will provide risk transfer, transparency, and more certainty. A futures market in healthcare is a product whose time has come.

  • Prospects For Healthcare Capital Markets In 2017
    Prospects For Healthcare Capital Markets In 2017

    As life sciences asset managers, our evaluation of the life science capital markets for the second quarter of 2017 is one of confidence, mediated by prudent caution. Our view has been based on a confluence of subjective and objective factors.

  • Funding For Biopharmas Targeting Urgent Bacterial Threats
    Funding For Biopharmas Targeting Urgent Bacterial Threats

    A Nevada woman’s death in 2016 from an untreatable bacterial infection called attention to the possibility of an “antibiotic apocalypse,” when even the most deadly bacterial strains will prove resistant to all available antibiotics. “Antibiotic development is not keeping pace with the emergence of antibiotic-resistant bacterial strains,” said Kevin Outterson, executive director of the new global public-private partnership, Combatting Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).

  • IP Due Diligence: 5 Questions You Must Ask In Corporate Transactions
    IP Due Diligence: 5 Questions You Must Ask In Corporate Transactions

    IP due diligence standards need to be continuously updated to stay current, especially, as biopharma companies increasingly pursue high-stakes, IP-intensive deals in which an overlooked IP issue can undermine the entire value of such a transaction. The following are the five questions you must ask in corporate transactions regarding IP due diligence.

  • Timeline And Developmental Activities When Resources Are Limited
    Timeline And Developmental Activities When Resources Are Limited

    It is increasingly rare that early-stage compounds or platform technologies are acquired without demonstration of clinical effect. Many years ago you could get funding for an idea, a piece of data, or a novel platform. With little exaggeration, funding could be generally raised as long as there was promise and the ability to tell a story, or until the concept was fully disproven.

  • Building A Biotech Hub – Austin Style
    Building A Biotech Hub – Austin Style

    There is a serious push to make Texas the “Third Coast” of biotech and Austin, in particular, a new hub for the industry.

  • Academia Finds New Ways To Partner With Pharma
    Academia Finds New Ways To Partner With Pharma

    For the past decade, academia and industry have become increasingly collaborative, finding ways to shed cautious attitudes and successfully advance programs together. Now, academia is taking a proactive, strategic approach that promises to further catalyze industry relationships and increase opportunities for commercialization and monetization of the most promising technologies.

  • Why More Incentives Are Needed To Tackle Antibiotic Resistance
    Why More Incentives Are Needed To Tackle Antibiotic Resistance

    Antibiotic resistance is a real and immediate threat that is beginning to garner the global attention it needs and deserves. During a meeting of the United Nations in September 2016, the entire General Assembly — 193 nations — reaffirmed its commitment to developing national action plans on combatting antibiotic resistance.

  • What JPM 2017 Revealed To Me
    What JPM 2017 Revealed To Me

    As I walked into a breakout session on at JPM, I couldn’t help but overhear people discussing the latest negative news to hit the biopharma industry.

  • What Gets Funded, What Dies Before It Gets To Pharma R&D
    What Gets Funded, What Dies Before It Gets To Pharma R&D

    Lots of people in our industry are wondering how to simultaneously bring value to patients and the organization. It’s a reasonable aspiration, but is it possible?

More Finance/Funding Articles